Chronic Migraine Clinical Trial
— IMPACTOfficial title:
Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic
Headache disorders are prevalent, disabling, under recognized, under diagnosed and under
treated. Migraine has a prevalence of 10% in men and 25% in women in Canada. The treatment
of migraine is based on patient education (lifestyle habit modification, trigger avoidance),
and pharmacological acute treatment and prophylaxis. A multidisciplinary approach allows a
repartition of tasks between different health professionals.
In a 2010 meeting, the Canadian Headache Society members supported the concept of Headache
Centers, and a headache nurse was judged as an essential component of such centers.
Gaul has reviewed the structured multidisciplinary approach that could be used in a headache
centre and the existing studies using such structures. Five studies did include a headache
nurse. No study did observe the impact of a nurse only. Resources in medical care are
limited. One study did use a program of 96 hours, which does not seem realistic on the
long-term and for a large pool of patients in a public hospital. Patients are not always
able to pay for paramedical help such as physiotherapy and psychotherapy. Even if they do,
finding a specialized therapist for chronic headache is difficult. Defining the role of a
nurse and demonstrating the impact on patient care is therefore a first step in the concept
of a headache center. Possible roles of a headache nurse according to Gaul are patient
education, follow-up of the treatment plan, addressing patient queries, and monitoring of
patient progress. The headache nurse may also participate in research projects. In a
hospital Headache Clinic, the nurse may be involved in intra-venous treatments and blood
sampling for research.
In summary, evidence to demonstrate the impact of a nurse in a headache clinic is lacking.
We propose to study this aspect prospectively. A study with positive findings would
encourage health ministers to fund and support headache nurses for headache centers across
Canada for headache management. Chronic headache and therefore chronic migraine would be a
focus of such centers, since most patients seen in specialized centers are chronic.
HYPOTHESIS: The addition of a headache nurse to the headache team will help the CHUM
Migraine Clinic to improve treatment outcome, and reduce the burden of headache. This
multidisciplinary approach will also allow a higher efficiency of the team.
Status | Completed |
Enrollment | 200 |
Est. completion date | November 2015 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
INCLUSION CRITERIA: - Age 18 or more - Diagnosis of migraine, chronic or episodic, at the first visit. We expect the majority of patients to suffer form frequent or chronic migraine. - Consent to participate in the CHUM Migraine Clinic IMPACT project. - For future post-hoc analysis, groups will be stratified according to baseline headache frequency (all severity included), assessed retrospectively at the first visit: - <6 headache days per month, - 6 to 14 headache days per month - 15 or more headache days per month EXCLUSION CRITERIA: - Patients whom first headache diagnosis is not migraine (for example post-traumatic headache, cluster headache, trigeminal neuralgia, facial pain). - Women with ongoing or planned pregnancy. - Patient with an active psychiatric condition (needing hospitalisation or psychosis). - Patient with mental retardation impairing assessment or follow-up. - Patient with an active medical condition which may lead to frequent hospitalisations (eg active cancer, organ graft, hemodialysis etc). This will be determined and detailed by the evaluating physician. - Active drug addiction or alcoholism. - Active follow-up at a pain clinic. - Patient speaking a language other than french and incapable to communicate in a reliable way. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | Hôpital Notre-Dame | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Notre-Dame Hospital, Montreal, Quebec, Canada | Allergan |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hit-6 score change | HIT-6 score change between inclusion and 8 month. | Baseline and 8 months | No |
Secondary | Frequency of moderate and severe headache days | Variation in the frequency of moderate or severe headache days per month between the first, fourth and eighth month after inclusion. | Baseline and 8 months | No |
Secondary | Frequency of headache days | Change in the frequency of headache days, all severity included, between the first month and the seventh and eight months following inclusion. | Baseline and 8 months | No |
Secondary | Chronic headache status | Percent of patients who were chronic (more than 3 months with >15 headache days per month, retrospective) at entry and were episodic at one year (according to calendars). | Baseline and 1 year | Yes |
Secondary | Medication overuse | Percent of patients with medication overuse at entry and were not overusing anymore at 8 months. | Baseline and 8 months | No |
Secondary | Acute medication intake | Change in the number of days per month with acute medication use between the first month after inclusion and the seventh and eight months following inclusion. | Baseline and 8 months | No |
Secondary | Efficacy of acute treatment | Percent of patients who succeeded in finding a successful and properly used acute treatment at month eight, according to four criteria: efficacy, reliability, absence of recurrence, absence of significant side effects. | at 8 months | No |
Secondary | Response rate to prophylactics | Percent of patients who did complete a successful (>50% response and no significant side-effects) preventive treatment trial at month eight after inclusion. | at 8 months | No |
Secondary | Short Form 12 score | Change in SF-12 scores between inclusion and third visit. SF-12 is a quality of life questionnaire. | Baseline and 8 months | No |
Secondary | Visits to the emergency department | Number of headache-related emergency department visits per patient during the year following their inclusion. | over 1 year | No |
Secondary | Severe adverse effects from treatments | Percent of patients with a severe adverse effect from a treatment (necessitating hospitalization, emergency visit or specific treatment). | over 1 year | Yes |
Secondary | Phone calls returned | Number of phone calls returned per month | per 1 month | No |
Secondary | Patient satisfaction | Satisfaction of patients, evaluated by a customized questionnaire. | at 8 months | No |
Secondary | Phone call return delay | Mean delay for returning the call (number of week days between the date of the call and the date of the return). | for each phone call, mean | No |
Secondary | Global improvement | Evaluation of physician of the global improvement of the patient. | at 8 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Completed |
NCT02514148 -
Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients
|
N/A | |
Enrolling by invitation |
NCT02291380 -
A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine
|
Phase 3 | |
Withdrawn |
NCT02122744 -
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
|
N/A | |
Completed |
NCT02122237 -
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
|
Phase 3 | |
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01709708 -
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
|
Phase 4 | |
Completed |
NCT01741246 -
Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging
|
N/A | |
Completed |
NCT01090050 -
Treximet in the Treatment of Chronic Migraine
|
Phase 4 | |
Recruiting |
NCT03507400 -
Introvision for Migraine and Headaches
|
N/A | |
Completed |
NCT04161807 -
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
|
N/A | |
Completed |
NCT03175263 -
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain
|
N/A | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT01700387 -
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
|
Phase 4 | |
Completed |
NCT01667250 -
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT01135784 -
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
|
Phase 2 | |
Completed |
NCT01496950 -
Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine
|
Phase 1 |